Monday June 26th 2017

‘Featured’ Archives

Prof. Lutz Harms on the origin and treatment of MS

Prof. Lutz Harms on the origin and treatment of MS

The Berlin neurologist tells us why there is still no cure for the autoimmune disorder, and how patients can be helped nonetheless. [Read More]

CCSVI 2013: ‘debunking,’ spin, and legal drama

CCSVI 2013: ‘debunking,’ spin, and legal drama

If there were a drinking game that called for taking a shot whenever the term chronic cerebrospinal venous insufficiency—or CCSVI—appeared in 2013 in a headline alongside “debunked” or “death knell,” we all would have been plastered well before New Year’s Eve. [Read More]

Wild goalie Josh Harding placed on I.R. to adjust to new MS medicine

Wild goalie Josh Harding placed on I.R. to adjust to new MS medicine

Josh Harding has been perhaps the feel-good story of the NHL season, putting up numbers unmatched for a goalie after revealing that he has multiple sclerosis. The Minnesota Wild goalie was placed on injured reserve Wednesday night to give him time to make adjustments to [Read More]

 Page 1 of 39  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]